Ionis Pharmaceuticals (IONS) said Monday that the company and partner AstraZeneca's (AZN) Wainzua received approval in the European Union to treat hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, or ATTRv-PN.
Wainzua was approved for ATTRv-PN treatment in the US in December 2023 and has received approvals in other countries, including the UK and Canada, the company said.
ATTRv-PN results in peripheral nerve damage with motor disability within five years of diagnosis. Without treatment, the disease is "generally fatal" within 10 years, Ionis said.
Shares of Ionis rose 1.4% in recent premarket activity, while AstraZeneca fell 1.7%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。